EWP
SMMT icon

Elevation Wealth Partners’s Summit Therapeutics SMMT Stock Holding History

Elevation Wealth Partners’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.74K Buy
+280
New +$4.19K ﹤0.01% 1117
2026
Q2 		– Sell
-91
Closed -$1.73K – 1352
2026
Q1 		$1.73K Buy
+91
New +$1.47K ﹤0.01% 933

Other funds holding SMMT

FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
CI
CX Institutional Auburn, Indiana $3.69B AUM 15.82% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return
MHR
Matthew Hamilton Rosenberg $558M AUM 12.28% 1-Year Est. Return
GWM
GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
MAM
Marquette Asset Management Minneapolis, Minnesota $766M AUM 16.04% 1-Year Est. Return
PS
Planning Strategies Lancaster, Pennsylvania $169M AUM

Elevation Wealth Partners's SMMT Position: Q3 2026 in Review

Elevation Wealth Partners opened a new position in Summit Therapeutics (SMMT) in Q3 2026: 280 shares worth $4.74K. The stake represents ﹤0.01% of the portfolio and ranks #1117 among its holdings. This is a return to the name: Elevation Wealth Partners previously reported a position in SMMT as recently as Q1 2026.

Elevation Wealth Partners first reported a position in SMMT in Q1 2026 and has held it in 2 quarters since. 10 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.

  • Elevation Wealth Partners held 280 shares of Summit Therapeutics worth $4.74K as of Q3 2026.
  • Summit Therapeutics was a new Elevation Wealth Partners position in Q3 2026.
  • Summit Therapeutics made up ﹤0.01% of Elevation Wealth Partners's portfolio in Q3 2026, its #1117 holding.
  • Elevation Wealth Partners first reported a position in Summit Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 10 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.

Based on Elevation Wealth Partners's 13F filing for Q3 2026, filed 7 Oct 2026.